Last reviewed · How we verify
Low dose lamotrigine
Low dose lamotrigine is a Anticonvulsant / Mood stabilizer Small molecule drug developed by Mario Negri Institute for Pharmacological Research. It is currently FDA-approved for Epilepsy (adjunctive therapy), Bipolar disorder (maintenance treatment, particularly bipolar depression), Off-label use in mood disorders and neuropathic pain. Also known as: Low lamotrigine.
Low-dose lamotrigine reduces neuronal excitability by blocking voltage-gated sodium channels and inhibiting glutamate release.
Low dose lamotrigine is used to study its efficacy and tolerability in newly diagnosed, previously untreated epilepsy. As a small molecule, lamotrigine works by blocking the sodium channel alpha subunit, which is involved in the regulation of neuronal excitability.
At a glance
| Generic name | Low dose lamotrigine |
|---|---|
| Also known as | Low lamotrigine |
| Sponsor | Mario Negri Institute for Pharmacological Research |
| Drug class | Anticonvulsant / Mood stabilizer |
| Target | Voltage-gated sodium channels; glutamate release modulation |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Lamotrigine stabilizes neuronal membranes primarily through sodium channel blockade, which prevents repetitive neuronal firing. At low doses, it also modulates glutamatergic neurotransmission by inhibiting the release of glutamate, an excitatory neurotransmitter. This dual mechanism makes it useful in conditions characterized by neuronal hyperexcitability or mood dysregulation.
Approved indications
- Epilepsy (adjunctive therapy)
- Bipolar disorder (maintenance treatment, particularly bipolar depression)
- Off-label use in mood disorders and neuropathic pain
Common side effects
- Rash (including Stevens-Johnson syndrome risk at higher doses)
- Dizziness
- Ataxia
- Diplopia
- Headache
- Nausea
- Tremor
Key clinical trials
- Ketogenic Diet for New-Onset Absence Epilepsy (PHASE3)
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- IV Ketamine Vs. in Esketamine for MDD TRD
- The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low dose lamotrigine CI brief — competitive landscape report
- Low dose lamotrigine updates RSS · CI watch RSS
- Mario Negri Institute for Pharmacological Research portfolio CI
Frequently asked questions about Low dose lamotrigine
What is Low dose lamotrigine?
How does Low dose lamotrigine work?
What is Low dose lamotrigine used for?
Who makes Low dose lamotrigine?
Is Low dose lamotrigine also known as anything else?
What drug class is Low dose lamotrigine in?
What development phase is Low dose lamotrigine in?
What are the side effects of Low dose lamotrigine?
What does Low dose lamotrigine target?
Related
- Drug class: All Anticonvulsant / Mood stabilizer drugs
- Target: All drugs targeting Voltage-gated sodium channels; glutamate release modulation
- Manufacturer: Mario Negri Institute for Pharmacological Research — full pipeline
- Therapeutic area: All drugs in Neurology / Psychiatry
- Indication: Drugs for Epilepsy (adjunctive therapy)
- Indication: Drugs for Bipolar disorder (maintenance treatment, particularly bipolar depression)
- Indication: Drugs for Off-label use in mood disorders and neuropathic pain
- Also known as: Low lamotrigine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing